Oct 27, 2024 · Impact of MitraClip on Hospitalization Rates in Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights From RESHAPE-HF2

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

Aug 28, 2024 · Tirzepatide, when used for weight loss under the brand name Zepbound, is now more affordable thanks to a self-pay option created by the manufacturer, Lilly. The discount is available through the company’s own online pharmacy. The drug, an agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, has previously been sold ...

Oct 17, 2024 · One of the major themes of this year’s meeting is intervening earlier to prevent disease, including with TAVI in aortic stenosis.

Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released by Eli Lilly on Wednesday. Tirzepatide (Zepbound; Eli Lilly) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, while semaglutide (Wegovy; Novo Nordisk) is ...

Jan 29, 2025 · STS 2025, bariatric surgery vs GLP-1s, defining obesity, pregnancy complications, and private-equity owned hospitals.

Nov 16, 2024 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with obesity and heart failure with preserved ejection (HFpEF), results of the SUMMIT trial show. The treatment benefit was driven by a significant reduction in the risk of worsening HF events ...

Dec 29, 2024 · It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then later in 2024, long-awaited data broke new ground for the early treatment of severe aortic stenosis. In February, the Evoque tricuspid valve replacement system (Edwards Lifesciences) became the first transcatheter tricuspid ...

Oct 28, 2024 · (UPDATED) While discussions about the lack of a mortality effect will continue, some say the findings may be enough to change guidelines.

Apr 14, 2024 · The best online resource for cardiology conference slides around the globe.